A new chromogranin A-dependent angiogenic switch activated by thrombin

Luca Crippa, Mimma Bianco, Barbara Colombo, Anna M. Gasparri, Elisabetta Ferrero, Y. Peng Loh, Flavio Curnis, Angelo Corti

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Angiogenesis, the formation of blood vessels from pre-existing vasculature, is regulated by a complex interplay of anti and proangiogenic factors. We found that physiologic levels of circulating chromogranin A (CgA), a protein secreted by the neuroendocrine system, can inhibit angiogenesis in various in vitro and in vivo experimental models. Structure-activity studies showed that a functional antiangiogenic site is located in the C-terminal region, whereas a latent anti-angiogenic site, activated by cleavage of Q76-K77 bond, is present in the N-terminal domain. Cleavage of CgA by thrombin abrogated its anti-angiogenic activity and generated fragments (lacking the C-terminal region) endowed of potent proangiogenic activity. Hematologic studies showed that biologically relevant levels of forms of full-length CgA and CgA1-76 (anti-angiogenic) and lower levels of fragments lacking the C-terminal region (proangiogenic) are present in circulation in healthy subjects. Blood coagulation caused, in a thrombin-dependent manner, almost complete conversion of CgA into fragments lacking the C-terminal region. These results suggest that the CgA-related circulating polypeptides form a balance of anti and proangiogenic factors tightlyregulated byproteolysis. Thrombin-induced alteration of this balance could provide a novel mechanism for triggering angiogenesis in pathophysiologic conditions characterized by prothrombin activation.

Original languageEnglish
Pages (from-to)392-402
Number of pages11
JournalBlood
Volume121
Issue number2
DOIs
Publication statusPublished - Jan 10 2013

Fingerprint

Chromogranin A
Thrombin
Switches
Neurosecretory Systems
Blood vessels
Prothrombin
Blood Coagulation
Coagulation
Blood Vessels
Healthy Volunteers
Blood
Theoretical Models
Chemical activation
Peptides
Proteins

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

A new chromogranin A-dependent angiogenic switch activated by thrombin. / Crippa, Luca; Bianco, Mimma; Colombo, Barbara; Gasparri, Anna M.; Ferrero, Elisabetta; Loh, Y. Peng; Curnis, Flavio; Corti, Angelo.

In: Blood, Vol. 121, No. 2, 10.01.2013, p. 392-402.

Research output: Contribution to journalArticle

Crippa L, Bianco M, Colombo B, Gasparri AM, Ferrero E, Loh YP et al. A new chromogranin A-dependent angiogenic switch activated by thrombin. Blood. 2013 Jan 10;121(2):392-402. https://doi.org/10.1182/blood-2012-05-430314
Crippa, Luca ; Bianco, Mimma ; Colombo, Barbara ; Gasparri, Anna M. ; Ferrero, Elisabetta ; Loh, Y. Peng ; Curnis, Flavio ; Corti, Angelo. / A new chromogranin A-dependent angiogenic switch activated by thrombin. In: Blood. 2013 ; Vol. 121, No. 2. pp. 392-402.
@article{ae60a8368a274a2780f2afe957522208,
title = "A new chromogranin A-dependent angiogenic switch activated by thrombin",
abstract = "Angiogenesis, the formation of blood vessels from pre-existing vasculature, is regulated by a complex interplay of anti and proangiogenic factors. We found that physiologic levels of circulating chromogranin A (CgA), a protein secreted by the neuroendocrine system, can inhibit angiogenesis in various in vitro and in vivo experimental models. Structure-activity studies showed that a functional antiangiogenic site is located in the C-terminal region, whereas a latent anti-angiogenic site, activated by cleavage of Q76-K77 bond, is present in the N-terminal domain. Cleavage of CgA by thrombin abrogated its anti-angiogenic activity and generated fragments (lacking the C-terminal region) endowed of potent proangiogenic activity. Hematologic studies showed that biologically relevant levels of forms of full-length CgA and CgA1-76 (anti-angiogenic) and lower levels of fragments lacking the C-terminal region (proangiogenic) are present in circulation in healthy subjects. Blood coagulation caused, in a thrombin-dependent manner, almost complete conversion of CgA into fragments lacking the C-terminal region. These results suggest that the CgA-related circulating polypeptides form a balance of anti and proangiogenic factors tightlyregulated byproteolysis. Thrombin-induced alteration of this balance could provide a novel mechanism for triggering angiogenesis in pathophysiologic conditions characterized by prothrombin activation.",
author = "Luca Crippa and Mimma Bianco and Barbara Colombo and Gasparri, {Anna M.} and Elisabetta Ferrero and Loh, {Y. Peng} and Flavio Curnis and Angelo Corti",
year = "2013",
month = "1",
day = "10",
doi = "10.1182/blood-2012-05-430314",
language = "English",
volume = "121",
pages = "392--402",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "2",

}

TY - JOUR

T1 - A new chromogranin A-dependent angiogenic switch activated by thrombin

AU - Crippa, Luca

AU - Bianco, Mimma

AU - Colombo, Barbara

AU - Gasparri, Anna M.

AU - Ferrero, Elisabetta

AU - Loh, Y. Peng

AU - Curnis, Flavio

AU - Corti, Angelo

PY - 2013/1/10

Y1 - 2013/1/10

N2 - Angiogenesis, the formation of blood vessels from pre-existing vasculature, is regulated by a complex interplay of anti and proangiogenic factors. We found that physiologic levels of circulating chromogranin A (CgA), a protein secreted by the neuroendocrine system, can inhibit angiogenesis in various in vitro and in vivo experimental models. Structure-activity studies showed that a functional antiangiogenic site is located in the C-terminal region, whereas a latent anti-angiogenic site, activated by cleavage of Q76-K77 bond, is present in the N-terminal domain. Cleavage of CgA by thrombin abrogated its anti-angiogenic activity and generated fragments (lacking the C-terminal region) endowed of potent proangiogenic activity. Hematologic studies showed that biologically relevant levels of forms of full-length CgA and CgA1-76 (anti-angiogenic) and lower levels of fragments lacking the C-terminal region (proangiogenic) are present in circulation in healthy subjects. Blood coagulation caused, in a thrombin-dependent manner, almost complete conversion of CgA into fragments lacking the C-terminal region. These results suggest that the CgA-related circulating polypeptides form a balance of anti and proangiogenic factors tightlyregulated byproteolysis. Thrombin-induced alteration of this balance could provide a novel mechanism for triggering angiogenesis in pathophysiologic conditions characterized by prothrombin activation.

AB - Angiogenesis, the formation of blood vessels from pre-existing vasculature, is regulated by a complex interplay of anti and proangiogenic factors. We found that physiologic levels of circulating chromogranin A (CgA), a protein secreted by the neuroendocrine system, can inhibit angiogenesis in various in vitro and in vivo experimental models. Structure-activity studies showed that a functional antiangiogenic site is located in the C-terminal region, whereas a latent anti-angiogenic site, activated by cleavage of Q76-K77 bond, is present in the N-terminal domain. Cleavage of CgA by thrombin abrogated its anti-angiogenic activity and generated fragments (lacking the C-terminal region) endowed of potent proangiogenic activity. Hematologic studies showed that biologically relevant levels of forms of full-length CgA and CgA1-76 (anti-angiogenic) and lower levels of fragments lacking the C-terminal region (proangiogenic) are present in circulation in healthy subjects. Blood coagulation caused, in a thrombin-dependent manner, almost complete conversion of CgA into fragments lacking the C-terminal region. These results suggest that the CgA-related circulating polypeptides form a balance of anti and proangiogenic factors tightlyregulated byproteolysis. Thrombin-induced alteration of this balance could provide a novel mechanism for triggering angiogenesis in pathophysiologic conditions characterized by prothrombin activation.

UR - http://www.scopus.com/inward/record.url?scp=84872327841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872327841&partnerID=8YFLogxK

U2 - 10.1182/blood-2012-05-430314

DO - 10.1182/blood-2012-05-430314

M3 - Article

VL - 121

SP - 392

EP - 402

JO - Blood

JF - Blood

SN - 0006-4971

IS - 2

ER -